secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021721
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q3 net loss narrows to $5.2M; ZEVASKYN first treatment delayed to Q4 2025
--------------------------------------------------------------------------------

- Net loss of $5.2M ($0.10/sh) vs $30.3M ($0.63/sh) in Q3 2024; R&D expense fell to $4.2M, SG&A rose to $19.3M on commercial launch.
- Cash $207.5M at Sep 30, expected to fund operations over two years without ZEVASKYN revenue.
- First ZEVASKYN patient treatment shifted to Q4 2025 after sterility assay false positive; biopsy collection resumed Nov 2025.
- Patient demand growing: 30 eligible patients identified at two QTCs; 12 product order forms received; three centers activated.
- Major commercial payers covering ~60% of RDEB patients; CMS J-code effective Jan 1, 2026; ABO-503 accepted into FDA RDEA program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/0001493152-25-021721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer